Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 20:17:767-776.
doi: 10.2147/OTT.S475219. eCollection 2024.

Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from ERCC2 rs13181

Nadiya Nurul Afifah  1   2 , Lanny Indah Permatasari  1 , Ajeng Diantini  3 , Ruri Intania  4 , Indra Wijaya  5 , Hideru Obinata  6 , Melisa Intan Barliana  1   7
Affiliations

Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from ERCC2 rs13181

Nadiya Nurul Afifah et al. Onco Targets Ther. .

Abstract

Purpose: Individual responses to platinum-based treatment for Non-Small Cell Lung Cancer (NSCLC) are influenced by genetic polymorphisms, including Single Nucleotide Polymorphisms (SNPs). This study aimed to explore the role of ERCC2 in the Nucleotide Excision Repair (NER) pathway for platinum-based chemotherapy in NSCLC. While ERCC2 is widely studied, data for Southeast Asian populations are lacking. Addressing this gap could improve personalized treatment strategies for NSCLC in this demographic.

Patients and methods: This study recruited 82 NSCLC patients with wildtype mutations of EGFR at Dr. H.A. Rotinsulu Lung Hospital, Bandung, and Dharmais Cancer Hospital, Jakarta. Data were collected prospectively from whole blood samples and medical records, while the effectiveness of chemotherapy was assessed by evaluating the response using RECIST 1.1 criteria on fourth cycle of chemotherapy.

Results: The results of this study showed the presence of genotype variation among the subjects, with frequency distribution as follows: AA genotype (82.9%), AC genotype (15.9%), and CC genotype (1.2%). The analysis of the association between ERCC2 rs13181 CC + AC versus AA with RECIST 1.1 yielded an odds ratio (OR) of 1.042 (95% CI: 0.292-3.715; p=0.950). A multivariate analysis that included cancer stage and chemotherapy regimen as additional variables produced an adjusted odds ratio (aOR) of 0.970 (95% CI: 0.263-3.568; p=0.963).

Conclusion: This study did not find statistically significant associations between ERCC2 rs13181 polymorphisms and chemotherapy responses. However, this research highlights the presence of genetic variation within the Indonesian population, with the AA genotype being the most prevalent, which may influence chemotherapy responses. The results provided preliminary data and lay the foundation for future comprehensive cohort observational investigations.

Keywords: ERCC2; Indonesia; RECIST 1.1; genetic polymorphism; platinum-based.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Similar articles

See all similar articles

References

    1. World Health Organization. Cancer Fact Sheets. WHO Press.
    1. Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics review 1975-2017 national cancer institute SEER cancer statistics review 1975-2017 national cancer institute. Nat Cancer Inst. 2017.
    1. Kemenkes RI. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. 2017.
    1. Srikrishnan A, Fuster MM, Montgrain PR. Curative stereotactic body radiotherapy is safe and effective in early stage non-small cell lung cancer: a single-center retrospective review of a cohort of veterans. Am J Respir Crit Care Med. 2018;197
    1. American Cancer Society. Lung cancer survival rates | 5-year survival rates for lung cancer. Am Cancer Society. 2019;7–9.